A Phase 2 interventional study of SBRT on all sites of metastatic disease+Apalutamide in Oligometastatic Hormone Sensitive Prostate Cancer, sponsored by Azienda Ospedaliero-Universitaria Careggi. Active, not recruiting at 1 site in Italy. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Azienda Ospedaliero-Universitaria Careggi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 339 studies in Prostatic Neoplasms with a site in Italy — 94 open to participants now, 143 under way, 36 of them phase 3. Prostatic Neoplasms · Italy.
Among the 339 studies in Prostatic Neoplasms with a site in Italy, this one is the 140th largest by planned enrollment of the 244 interventional ones that give a count, is one of 27 that started in 2023, is one of 54 in phase 2, reaches primary completion later than 32 of the 142 other live ones, and was the 220th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →94 of the 339 studies in Prostatic Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
Niguarda Hospital · Sites in Italy
Ages 18–85 · Men only
AstraZeneca · Sites in Italy, United States, Austria and 18 more countries
Ages 18+ · Men only
Istituto Clinico Humanitas · Sites in Italy
Ages 18+ · Men only
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD · Sites in Italy, France, Germany and 2 more countries
Ages 18+ · Men only
AstraZeneca · Sites in Italy, United States, Australia and 4 more countries
Ages 18–99 · Men only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
339 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 70 · Phase 3 105 · Phase 4 8
First in 1992; this study’s year is marked. 27 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 220 across the 244 interventional studies, 280 across the 93 observational. Of the 166 that completed or were terminated, 68 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 339 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliero-Universitaria Careggi is the lead sponsor of 78 studies on the registry; 23 are open to participants now.
Azienda Ospedaliero-Universitaria Careggi has 6 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
35 of the studies in Prostatic Neoplasms with a site in Italy that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT06551324Phase 3PfizerA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | 2027-02-28 |
| NCT06717711Phase 3Regina Elena Cancer InstituteLow-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers | 2027-02-28 |
| NCT06122584Phase 3ABX advanced biochemical compounds GmbHDiagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer | 2027-03 |
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
Add all 35 to your calendar (.ics) → With an account.
Among the 339 studies in Prostatic Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Final results from TITAN trial showed that apalutamide plus ADT improved OS in a population of patients with metastatic hormone sensitive prostate cancer (mHSPC), if compared to ADT alone. However, stereotactic body radiotherapy (SBRT) showed to improve outcomes of oligometastatic patients if compared to systemic therapy alone within modern randomized trial, including a mixed cohort of different pathologies. However, there are no trials specifically exploring the benefit offered by SBRT in oligometastatic mHSPC treated with Apalutamide if compared to Apalutamide alone associated to Androgen deprivation therapy. Thus, a randomized trial was designed to test specifically the hypotesis that SBRT will improve outcome in a selected population of oligometastatic mHSPC treated with Apalutamide and ADT, undergoing baseline staging according to local reimbursability.
Prospective Phase II randomized superiority study, open label, multicentric. Patients with Oligometastatic hormone sensitive prostate cancer defined as presence of ≤ 5 non-visceral metastatic lesions and treated with androgen deprivation treatment associated with Apalutamide will be randomized to receive standard systemic treatment alone or concomitant SBRT on all sites of metastatic disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Androgen Deprivation therapy and Apalutamide
Combination Product: SBRT on all sites of metastatic disease+Apalutamide
Androgen Deprivation therapy and Apalutamide and SBRT on all sites of metastatic disease
Combination Product: SBRT on all sites of metastatic disease+Apalutamide
oral Apalutamide 240 mg daily+ stereotactic body radiotherapy on all metastatic sites of disease, administered in 1-8 fractions for a total EQD2 of 50 Gy with an alpha/beta of 10.
Complete biochemical response
Rate of patients with complete biochemical response (PSA \< 0.2 ng/ml)
Time frame: 6 months after treatment start.
Freedom from biochemical progression
Biochemical progression defined according to Prostate Cancer Working Group Criteria
Time frame: 2 years after treatment
Freedom from radiological progression
radiological progression defined according to Prostate Cancer Working Group Criteria
Time frame: 2 years after treatment
Rate of adverse events
measured according to Common Terminology Criteria for Adverse Events
Time frame: 2 years after treatment
Overall Survival
Time between randomization and death from any cause
Time frame: 2 years after treatment
Cancer Specific Survival
Time between randomization and death from prostate cancer
Time frame: 2 years after treatment
Health related quality of life
Measured with European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire.
Time frame: 2 years after treatment
Health related quality of life
Measured with EORTC QLQ-PR25 questionnaire
Time frame: 2 years after treatment
Plan to share: No
Ran from Mar 2023 to primary completion in Sep 2025, 30 months.
Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's 30 months is below that.
Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Sep 2024 → Sep 2025 and completion Mar 2025 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliero-Universitaria Careggi